| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 4.06 | 0.08 (+2.01%) | 2.60 - 5.58 | 1.3 million (Above Avg) |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 3.99 |
|---|---|
| Previous Close | 3.98 |
| Day's Range | 3.99 - 4.07 |
| Market Cap | 512.3M |
| Avg Volume (10 Day) | 1.0M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.04 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Antares Pharma to Present at the Bank of America Merrill Lynch 2013 Healthcare Conference
Business Wire - Thursday 05/09/2013 7:00 AM ET
Antares Pharma Reports First Quarter 2013 Operating and Financial Results
Business Wire - Wednesday 05/08/2013 7:00 AM ET
Antares Pharma to Host First Quarter 2013 Operating and Financial Results Conference Call
Business Wire - Wednesday 05/01/2013 7:00 AM ET
| ATRS | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 2.46% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 25.31 |
| Company | Last | Change |
|---|---|---|
| Merit Medical Systems Inc | 10.18 | +2.62% |
| Atrion Corp | 209.29 | +0.16% |
| AngioDynamics Inc | 10.68 | 0.00% |
| Tornier NV | 16.42 | -0.42% |
| STAAR Surgical Co | 8.64 | +0.47% |
Data is delayed by at least 15 min.